59.3 Chronic Myopathies & Fibromyalgia Syndrome

Fibromyalgia Syndrome: Neurobiology & Centralized Pain Amplification

Fibromyalgia Syndrome (FMS) is a common chronic pain disorder affecting 2% to 4% of the global population, characterized by widespread musculoskeletal aching, unrefreshing sleep, debilitating fatigue, and cognitive dysfunction. In 2017, the International Association for the Study of Pain (IASP) formally recognized a third mechanistic descriptor for chronic pain: Nociplastic Pain—defined as pain that arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage activating peripheral nociceptors, nor evidence of primary lesion or disease of the somatosensory nervous system. Fibromyalgia serves as the prototypical nociplastic centralized pain disorder.

Neurobiological Mechanisms of Central Sensitization

Rigorous neuroimaging, neurochemical, and quantitative sensory testing (QST) studies have demonstrated that fibromyalgia is not a psychological or peripheral muscle/joint disease, but a neurobiological disorder of centralized pain regulation ("the central volume control setting is turned up high"):

1. Augmented Ascending Nociceptive Facilitation: Cerebrospinal fluid (CSF) analysis in patients with fibromyalgia reveals a 2- to 3-fold elevation in Substance P, as well as significantly elevated concentrations of Glutamate and Nerve Growth Factor (NGF). Excessive synaptic glutamate binds postsynaptic N-methyl-D-aspartate (NMDA) receptors in the dorsal horn of the spinal cord, precipitating temporal summation (the "wind-up" phenomenon), whereby repetitive, low-intensity peripheral sensory inputs produce progressive, escalating amplification of pain signals.
2. Deficient Descending Inhibitory Pain Pathways: In healthy individuals, descending bulbospinal tracts originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) release serotonin and norepinephrine into the dorsal horn, suppressing incoming pain traffic (diffuse noxious inhibitory control / Conditioned Pain Modulation [CPM]). In fibromyalgia, CSF levels of serotonin, norepinephrine, and dopamine metabolites are markedly reduced, indicating a profound failure of endogenous descending analgesic gating.
3. Functional Neuroimaging Alterations: Functional Magnetic Resonance Imaging (fMRI) reveals exaggerated Blood-Oxygen-Level-Dependent (BOLD) activation of the cerebral "pain matrix" (somatosensory cortices S1 and S2, anterior cingulate cortex [ACC], and insular cortex) in response to light tactile pressure that healthy controls perceive as painless (Allodynia) and exaggerated pain responses to mildly painful stimuli (Hyperalgesia). Furthermore, resting-state fMRI demonstrates hyperconnectivity between the default mode network (DMN) and the pro-nociceptive insular cortex.
4. Sleep Architecture & Neuroendocrine Derangement: Polysomnography characteristically demonstrates alpha-delta sleep: the continuous abnormal intrusion of rapid alpha waves (7-12 Hz, typical of wakefulness) into deep, slow-wave delta sleep (stage 3 and 4 non-REM sleep). This disrupted architecture prevents restorative physiological sleep, suppresses nocturnal human growth hormone release, and impairs muscle tissue repair. Patients also exhibit blunting of the hypothalamic-pituitary-adrenal (HPA) axis with an abnormal, flattened diurnal cortisol curve.

---

Clinical Presentation & The Symptom Complex

                  THE TETRAD OF CORE FIBROMYALGIA MANIFESTATIONS

   Clinical Domain         Phenotypic Features                                   Pathophysiological Correlate
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Widespread Pain         Aching, burning, gnawing, stiffness affecting muscles, Central sensitization; lower pain thresholds
                           joints, and soft tissues bilaterally, above and       across all dermatomal / myotomal levels
                           below the waist, and throughout the axial skeleton
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Debilitating Fatigue    Severe physical exhaustion unalleviated by rest;      HPA axis blunting, neuroendocrine dysregulation,
                           most severe upon waking; exercise intolerance         depleted central monoamines
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Non-Restorative Sleep   Waking feeling completely unrefreshed ("like I never  Alpha-wave intrusion into delta slow-wave sleep;
                           slept" or "run over by a truck"); frequent awakenings absence of restorative stage 3/4 non-REM sleep
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cognitive Dysfunction   Slowed processing speed, impaired working memory,     Altered insular-DMN connectivity; interference
   ('Fibro Fog')           poor concentration, word-finding difficulty           from continuous nociceptive processing
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Overlapping Somatosensory Syndromes

Fibromyalgia rarely occurs in isolation; it characteristically clusters with other functional centralized somatic conditions:

• Irritable Bowel Syndrome (IBS) (present in 50% to 70% of patients): Recurrent abdominal pain, bloating, and altered bowel habits (diarrhea/constipation) driven by visceral hyperalgesia.
• Temporomandibular Disorder (TMD): Bilateral facial pain, jaw clicking, and masticatory muscle tenderness.
• Chronic Headaches: Severe tension-type headaches and migraines (present in >50%).
• Interstitial Cystitis / Bladder Pain Syndrome: Pelvic pain, urinary frequency, urgency, and suprapubic discomfort with sterile urine cultures.
• Subjective Neurological Dysesthesias: Numbness, tingling, or "electric crawling" sensations in the hands and feet without objective dermatomal sensory deficits or motor weakness.

---

Evolution of Diagnostic Criteria: 1990 vs. 2016 Revised ACR Criteria

Historical Context: The Flawed 1990 Tender Point Examination

The initial 1990 American College of Rheumatology (ACR) criteria required: 1) A history of chronic widespread pain for >=3 months, AND 2) Pain on digital palpation (with approximately 4 kg/cm² of force, enough to blanch the examiner's thumbnail) at at least 11 of 18 specific tender point sites. The 1990 criteria were severely flawed:

• Primary care clinicians rarely performed the tender point exam correctly or consistently;
• Male patients were heavily underdiagnosed because men naturally have higher mechanical pressure thresholds, falsely cementing a perceived 9:1 female predominance;
• Most critically, the 1990 criteria completely ignored the defining non-pain symptoms: sleep disruption, profound fatigue, and cognitive dysfunction.

The 2016 Revised ACR Diagnostic Criteria

The ACR revised criteria completely eliminated the manual tender point examination, replacing it with a validated, quantitative clinical scoring system based on two validated scales:

                  2016 REVISED ACR DIAGNOSTIC CRITERIA SCORING

   Diagnostic Metric                  Definition & Scoring Mechanism
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Widespread Pain Index (WPI)        Counts the number of painful anatomical areas over the PAST 7 DAYS (Score: 0 - 19):
                                      • Left Shoulder girdle   • Right Shoulder girdle  • Left Hip / Buttock
                                      • Left Upper arm         • Right Upper arm        • Right Hip / Buttock
                                      • Left Lower arm         • Right Lower arm        • Left Upper leg
                                      • Left Lower leg         • Right Lower leg        • Right Upper leg
                                      • Left Jaw               • Right Jaw              • Right Lower leg
                                      • Chest                  • Abdomen                • Neck
                                      • Upper back             • Lower back
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Symptom Severity Scale (SSS)       Part 2a: Core Symptoms (Score 0=none, 1=mild, 2=moderate, 3=severe over past week):
                                      1. Fatigue (0 - 3)
                                      2. Waking unrefreshed (0 - 3)
                                      3. Cognitive symptoms / "fibro fog" (0 - 3)
                                      Part 2b: Somatic Symptoms (Score 0 to 3 total):
                                      Presence during previous 6 months of: Headaches (0/1), Pain/cramps in
                                      lower abdomen (0/1), and Depression (0/1). (Total SSS Score: 0 - 12)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

The Formal Diagnostic Rule (2016 Update)

A patient meets formal diagnostic criteria for Fibromyalgia if ALL FOUR of the following conditions are satisfied:

1. Score Cutoff: WPI >= 7 AND SSS >= 5, OR WPI 4 to 6 AND SSS >= 9;
2. Generalized Pain Distribution: Pain is present in at least 4 of 5 anatomical regions:
   • Region 1 (Left Upper): Left shoulder, left upper arm, left lower arm
   • Region 2 (Right Upper): Right shoulder, right upper arm, right lower arm
   • Region 3 (Left Lower): Left hip/buttock, left upper leg, left lower leg
   • Region 4 (Right Lower): Right hip/buttock, right upper leg, right lower leg
   • Region 5 (Axial): Neck, upper back, lower back, chest, or abdomen
3. Duration: Symptoms have been present at a similar, consistent level for at least 3 months;
4. Validity with Other Illnesses: A diagnosis of fibromyalgia is valid irrespective of other diagnoses. Fibromyalgia is NO LONGER a diagnosis of exclusion. A patient can have both active Rheumatoid Arthritis or Systemic Lupus Erythematosus and concomitant Fibromyalgia (secondary/concomitant fibromyalgia occurs in 15% to 30% of patients with inflammatory rheumatologic disease).

---

Prudent Diagnostic Workup & Avoiding Over-Investigation

Because fibromyalgia produces diffuse aching, patients frequently undergo exhaustive, expensive, and unnecessary medical testing. The primary care physician must execute a targeted, rational initial laboratory evaluation aimed strictly at ruling out common organic mimics, while aggressively avoiding extensive autoimmune panels.

The Targeted Baseline Laboratory Panel

• Complete Blood Count (CBC): Rules out occult anemia, hematologic malignancies, and cytopenias.
• Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): CRITICAL EXAM PEARL: ESR and CRP are strictly NORMAL in primary fibromyalgia. An elevated ESR or CRP is a major red flag indicating an occult systemic inflammatory disease (e.g., Polymyalgia Rheumatica, Rheumatoid Arthritis, systemic vasculitis, occult infection, or malignancy) and points away from isolated fibromyalgia.
• Thyroid-Stimulating Hormone (TSH): Rules out hypothyroidism, which mimics fibromyalgia with fatigue, diffuse myalgias, weight gain, constipation, and cognitive slowing.
• Serum Creatine Kinase (CK): Strictly NORMAL in fibromyalgia. An elevated CK indicates a true myopathy (inflammatory myositis, statin-induced myopathy, muscular dystrophy, or hypothyroid myopathy).
• Serum Calcium and 25-OH Vitamin D: Evaluates for hyperparathyroidism, hypocalcemia, and severe osteomalacia.

[!CAUTION] THE HAZARD OF ORDERING ROUTINE ANA AND RHEUMATOID FACTOR Antinuclear Antibodies (ANA) and Rheumatoid Factor (RF) should NEVER be ordered routinely in patients presenting with chronic widespread pain in the absence of objective physical signs of connective tissue disease (e.g., true inflammatory joint synovitis/effusion, malar rash, discoid lesions, oral ulcers, photosensitivity, Raynaud phenomenon, sclerodactyly, or alopecia). In the general population, up to 20% to 30% of healthy women have a low-positive ANA titer (1:40 to 1:80). Ordering an ANA in a low-prevalence setting produces a devastatingly high false-positive rate, precipitating severe patient anxiety, inappropriate rheumatology referrals, and dangerous misdiagnoses that subject patients to toxic, unnecessary immunosuppressive therapies.

---

Comprehensive Management of Fibromyalgia

Successful management of fibromyalgia requires a patient-centered, multimodal approach that integrates non-pharmacologic therapies as the primary foundation, supplemented by targeted, evidence-based pharmacotherapies.

                  EVIDENCE-BASED MANAGEMENT OF FIBROMYALGIA SYNDROME

   Treatment Modality        Specific Therapeutic Agent             Clinical Directive & Mechanism of Action
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   FOUNDATIONAL CORE         • Graded Aerobic Exercise              MOST EFFECTIVE PROVEN INTERVENTION (walking, aquatic
   (Non-Pharmacologic)                                              therapy, cycling); "start low and go slow"
                             • Cognitive Behavioral Therapy (CBT)   Reduces pain catastrophizing, enhances coping mechanisms
                             • Sleep Hygiene Education              Fixed sleep schedule, blue-light reduction, no midday caffeine
                             • Patient Education & Validation       Validates neurobiological pain; reduces healthcare utilization
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   FDA-APPROVED              • DULOXETINE (Cymbalta)                SNRI (30 - 60 mg daily); boosts descending inhibition;
   PHARMACOTHERAPY                                                  improves pain, fatigue, and comorbid depression
                             • MILNACIPRAN (Savella)                SNRI (50 mg BID); preferential norepinephrine reuptake
                                                                    inhibition; improves pain, fatigue, and "fibro fog"
                             • PREGABALIN (Lyrica)                  Alpha-2-delta ligand (150 - 450 mg/day in divided doses);
                                                                    reduces glutamate/substance P; restores slow-wave sleep
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   EVIDENCE-BASED            • Cyclobenzaprine (Flexeril)           5 to 10 mg at bedtime; 5-HT2 receptor antagonist;
   OFF-LABEL THERAPY                                                improves sleep architecture and morning stiffness
                             • Amitriptyline (Elavil)               10 to 25 mg at bedtime; tricyclic antidepressant;
                                                                    improves non-restorative sleep; anticholinergic side effects
                             • Gabapentin (Neurontin)               Alternative alpha-2-delta ligand (300 - 1800 mg/day)
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   STRICTLY CONTRAINDICATED  • OPIOID ANALGESICS                    INEFFECTIVE for centralized nociplastic pain; triggers
   (DO NOT PRESCRIBE)        (Oxycodone, Codeine, Tramadol)         OPIOID-INDUCED HYPERALGESIA (OIH), dependence, falls
                             • SYSTEMIC CORTICOSTEROIDS             ABSOLUTELY INEFFECTIVE (no tissue inflammation);
                             (Prednisone, Methylprednisolone)       severe iatrogenic morbidity (osteoporosis, Cushingoid)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Non-Pharmacologic Therapy: The First-Line Foundation

Non-pharmacologic modalities provide the highest long-term effect sizes in clinical trials and must be established before or alongside medications:

• Graded Low-Impact Aerobic Exercise: The single most effective therapy. Modalities include brisk walking, stationary cycling, swimming, and warm-water pool aquatic therapy. The crucial clinical instruction is "start low and go slow": patients should begin with just 5 to 10 minutes of gentle exercise 2 to 3 days per week and titrate upward by 10% every 1 to 2 weeks toward a target of 30 to 45 minutes of moderate aerobic activity 3 to 4 days per week. Initiating vigorous exercise abruptly triggers severe post-exertional symptom flares and leads to immediate treatment abandonment.
• Cognitive Behavioral Therapy (CBT): Focuses on identifying and reframing cognitive distortions, decreasing pain catastrophizing, pacing daily physical activities to prevent "boom-and-bust" cycles, and developing active behavioral coping strategies.
• Sleep Hygiene: Establishing rigid sleep-wake times, maintaining a dark and cool bedroom environment, eliminating screens 2 hours prior to bed, and eliminating caffeine after noon.

2. FDA-Approved Pharmacotherapies: Dosing & Clinical Selection

Pharmacotherapy should be viewed as an adjunct to facilitate participation in exercise and CBT, rather than a standalone cure. Medications should be selected based on the patient's dominant symptom profile:

• Duloxetine (Cymbalta): Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Initial dose: 30 mg orally once daily in the morning for 1 week to minimize nausea, then titrate to the target therapeutic dose of 60 mg once daily. Enhances descending serotonergic and noradrenergic inhibitory pain gating. Ideal first-line agent when fibromyalgia co-exists with major depressive disorder, generalized anxiety, or severe chronic fatigue. Common adverse effects include nausea, dry mouth, insomnia, constipation, and mild blood pressure elevations.
• Milnacipran (Savella): SNRI with a distinct pharmacodynamic profile exhibiting greater potency for norepinephrine reuptake inhibition than serotonin (approximately 3:1 ratio). Dose: Titrate over 1 to 2 weeks to 50 mg orally twice daily (100 mg/day). Highly effective for patients in whom fatigue and cognitive dysfunction ("fibro fog") predominate. Adverse effects include nausea, headache, tachycardia, palpitations, hypertension, and hyperhidrosis.
• Pregabalin (Lyrica): Alpha-2-delta ligand. Initial dose: 75 mg orally twice daily (or 50 mg three times daily; 150 mg/day), titrating over 1 to 2 weeks to 150 mg twice daily (300 mg/day); maximum dose 450 mg/day. Binds presynaptic voltage-gated P/Q-type calcium channel alpha-2-delta subunits in the spinal cord dorsal horn, reducing calcium influx and inhibiting the exocytosis of glutamate and substance P. Highly preferred when severe non-restorative sleep and anxiety predominate, as pregabalin significantly increases restorative slow-wave sleep. Common adverse effects include dizziness, somnolence, peripheral edema, ataxia, and weight gain. Dose adjustment is mandatory in renal impairment.

3. Strictly Contraindicated Medications in Fibromyalgia

• Opioids Are Strictly Contraindicated: Controlled trials consistently show that opioids (including codeine, hydrocodone, oxycodone, morphine, and tramadol) are completely ineffective for centralized nociplastic pain. Furthermore, chronic opioid administration downregulates endogenous mu-opioid receptors, activates spinal microglial toll-like receptor 4 (TLR-4), and induces Opioid-Induced Hyperalgesia (OIH)—a paradoxical, severe amplification of widespread pain sensitivity. Opioids cause physical dependence, addiction, accidental overdose, sedation, cognitive worsening, and severe constipation.
• Systemic Corticosteroids Are Strictly Contraindicated: Fibromyalgia is devoid of systemic or synovial tissue inflammation. Corticosteroids (e.g., prednisone, methylprednisolone) have zero clinical efficacy and expose patients to life-threatening complications, including osteoporotic fractures, avascular necrosis, diabetes mellitus, adrenal insufficiency, and severe weight gain.

---

Differential Diagnosis of Chronic Myopathies

When evaluating patients with chronic musculoskeletal symptoms, primary care clinicians must distinguish true objective muscular weakness from the diffuse pain, stiffness, and subjective fatigue characteristic of fibromyalgia. A patient with fibromyalgia complains that "everything hurts and I feel weak," but demonstrates normal manual muscle testing (5/5 strength throughout). Conversely, patients with true myopathies exhibit objective weakness (e.g., inability to rise from a chair without using hands, difficulty lifting arms above shoulders) and often possess abnormal muscle enzymes.

                  DIFFERENTIAL DIAGNOSIS OF CHRONIC MYOPATHIES

   Disorder                Clinical Presentation                  Creatine Kinase (CK)   Distinguishing Diagnostic Features & Biopsy
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Statin-Induced          Bilateral symmetric proximal aching,   Mild elevation to      Symptoms resolve 2-4 weeks post-statin stop;
   Myopathy                stiffness, or weakness after statin    marked (> 10x ULN in   ANTI-HMGCR ANTIBODIES in necrotizing autoimmune
                           initiation or dose titration           true myositis)         myopathy (IMNM) that persists after stopping drug
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Hypothyroid             Proximal muscle weakness, cramping,    ELEVATED               ELEVATED TSH, low free T4; DELAYED RELAXATION
   Myopathy                fatigue, and sluggish deep tendon      (Typically 5 - 10x     OF DEEP TENDON REFLEXES (pseudomyotonia);
                           reflexes                               ULN; up to 50x)        myoedema on muscle percussion; resolves w/ levothyroxine
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Glucocorticoid-Induced  Insidious, PAINLESS symmetric proximal COMPLETELY NORMAL       Fast-twitch Type IIb muscle fiber atrophy;
   Myopathy                weakness (pelvic >> shoulder girdle);  (CK normal; ESR/CRP    develops with prednisone >= 20 mg/day for > 4-6 wks;
                           difficulty rising from low chair       normal)                resolves with steroid dose reduction & resistance PT
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Polymyositis /          Subacute symmetric proximal weakness   MARKEDLY ELEVATED      SKIN SIGNS IN DERMATOMYOSITIS (Heliotrope rash,
   Dermatomyositis         (neck flexors, deltoids, hip flexors); (10 - 50x ULN;         Gottron papules, Shawl sign, mechanic's hands);
                           dysphagia in 30-40% of patients        elevated aldolase)     Anti-Jo-1 antibodies; cancer screening mandatory in DM
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Inclusion Body          Older adults (> 50y); Male > Female;   NORMAL TO MILDLY       ASYMMETRIC WEAKNESS OF DEEP FINGER FLEXORS
   Myositis (IBM)          insidious progression over years;      ELEVATED (< 10x ULN;   (FDP: cannot grip objects/turn keys) AND QUADRICEPS
                           frequent falls (knee buckling)         often 300 - 800 U/L)   (falls); Biopsy: RIMMED VACUOLES with amyloid/tau
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Nuances of Major Myopathic Entities

1. Statin-Associated Muscle Symptoms (SAMS):
   • Statin Myalgia: Muscle aching or stiffness without objective weakness and with a normal CK. Management: Temporarily discontinue the statin for 2 to 4 weeks until symptoms resolve; rechallenge at a lower dose, switch to a hydrophilic statin (pravastatin, rosuvastatin), or initiate an alternate-day dosing schedule (e.g., rosuvastatin 5 mg twice weekly) or non-statin lipid-lowering therapy (ezetimibe, PCSK9 inhibitors).
   • Statin-Induced Immune-Mediated Necrotizing Myopathy (IMNM): A rare autoimmune disorder triggered by statin exposure. Presents with progressive, severe proximal weakness and markedly elevated CK (typically >10-20x ULN) that continues to worsen even after the statin is stopped. Diagnosis is confirmed by anti-HMG-CoA reductase (anti-HMGCR) autoantibodies and muscle biopsy showing myofiber necrosis with minimal inflammatory infiltrate. Requires aggressive immunosuppression with high-dose corticosteroids, methotrexate, and IVIG.
2. Hypothyroid Myopathy:
   • Hypothyroidism commonly presents with proximal muscle weakness, fatigue, muscle stiffness, and cramping. Physical examination reveals delayed relaxation of deep tendon reflexes ("hung-up" reflexes or pseudomyotonia). Percussion of the muscle belly may elicit myoedema—a transient, localized mounding or swelling of muscle tissue lasting several seconds caused by delayed calcium re-uptake into the sarcoplasmic reticulum.
   • Laboratory evaluation reveals markedly elevated serum CK (often 5 to 10 times ULN, occasionally up to 50 times ULN) accompanied by an elevated TSH and low free T4. Muscle symptoms and enzyme elevations resolve completely over 2 to 6 months following thyroid hormone replacement with levothyroxine.
3. Glucocorticoid-Induced Myopathy:
   • The most common drug-induced toxic myopathy. Caused by high-dose or prolonged systemic corticosteroid therapy (prednisone >=20 mg/day for >4-6 weeks, or fluorinated steroids such as dexamethasone and triamcinolone).
   • Presents as insidious, painless, symmetric proximal muscle weakness, predominantly involving the pelvic girdle (difficulty rising from a chair or climbing stairs; upper extremities and neck muscles are relatively spared).
   • Cardinal Diagnostic Feature: Serum Creatine Kinase (CK) is COMPLETELY NORMAL, and ESR/CRP are normal. Pathophysiology involves selective catabolism and atrophy of fast-twitch glycolytic Type IIb muscle fibers. Management consists of tapering the corticosteroid to the lowest possible dose or switching to alternate-day dosing, combined with resistance physical therapy.
4. Inclusion Body Myositis (IBM):
   • The most common acquired myopathy in individuals aged >50 years, with a strong male predominance (2:1).
   • Characterized by an insidious onset over years and a highly distinctive ASYMMETRIC pattern of weakness involving both proximal and distal muscle groups:
     • Deep Finger Flexors: Selective weakness and wasting of the flexor digitorum profundus (FDP) and flexor pollicis longus (FPL). Patients cannot make a tight fist, turn door keys, open jars, or carry grocery bags.
     • Quadriceps Femoris: Severe atrophy of the quadriceps leads to early knee buckling during ambulation and recurrent, traumatic falls.
     • Pharyngeal Muscles: Severe dysphagia occurs in 40% to 60% of patients.
   • Laboratory testing reveals a normal or only mildly elevated CK (typically <10x ULN). Muscle biopsy is diagnostic, demonstrating endomysial inflammation, rimmed vacuoles containing basophilic debris, and cytoplasmic/nuclear inclusions of amyloid and hyperphosphorylated tau protein.
   • Crucially, IBM is refractory to corticosteroids and conventional immunosuppressive medications. Treatment focuses on supportive physical therapy, assistive walking devices, fall prevention, and swallowing evaluations.